1. Home
  2. SOBR vs LIXT Comparison

SOBR vs LIXT Comparison

Compare SOBR & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SOBR Safe Inc.

SOBR

SOBR Safe Inc.

HOLD

Current Price

$1.38

Market Cap

2.4M

ML Signal

HOLD

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$4.21

Market Cap

25.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOBR
LIXT
Founded
2004
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Newspapers/Magazines
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4M
25.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SOBR
LIXT
Price
$1.38
$4.21
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
69.8K
106.6K
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$364,164.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
98.07
N/A
52 Week Low
$1.27
$0.64
52 Week High
$22.00
$6.26

Technical Indicators

Market Signals
Indicator
SOBR
LIXT
Relative Strength Index (RSI) 29.96 52.59
Support Level $1.40 $3.50
Resistance Level $2.17 $4.31
Average True Range (ATR) 0.15 0.31
MACD 0.01 0.00
Stochastic Oscillator 0.00 83.16

Price Performance

Historical Comparison
SOBR
LIXT

About SOBR SOBR Safe Inc.

Sobr Safe Inc provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. Its technologies are integrated within robust and scalable data platform, producing statistical and measurable user and business data. It developed the scalable, patent-pending ea4 software platform for non-invasive alcohol detection and identity verification, a solution that has current and potential applications. It generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: